Companies: 10,795·Total market cap: $144.5T
Kalaris Therapeutics Inc

Kalaris Therapeutics Inc

KLRSNASDAQHealthcare● Active
$4.17
$-0.27(-6.08%)
Market Cap$77990242
P/E Ratio—
52W High$11.88
52W Low$2.14
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

Kalaris Therapeutics Inc (KLRS) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · KLRS · as of Jun 9, 2026

Key Statistics

EPS (TTM)$-2.15klrs eps ttm · klrs earnings per shareEarnings history
PE Ratio (TTM)—klrs pe ratio ttm · klrs price to earningsPE Ratio deep dive
Revenue (TTM)0.00klrs revenue ttm · klrs annual revenueFull revenue history
Dividend YieldNo Dividenddoes klrs pay dividends · klrs dividend yieldDividend history
Shares Outstanding15.3Mklrs shares outstanding · klrs floatShares outstanding history
Next EarningsAug 12, 2026Est.klrs earnings date · klrs next earningsEarnings history

Explore Kalaris Therapeutics Inc Data

klrs stock data · financials
Market Cap$78.0Mklrs market cap · klrs valuation
Analyst Forecast$18 · Buy
DividendsNo Dividenddoes kalaris therapeutics inc pay dividends · klrs dividend yield
Revenue—kalaris therapeutics inc annual revenue · klrs revenue
EarningsEPS $-2.85+75.70%klrs earnings · klrs eps
PE Ratio—klrs pe ratio · klrs price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
kalaris therapeutics inc revenue · klrs revenue 2025
FY 2025Net Income-$43.4M▲ +26.09% YoY
202320242025
kalaris therapeutics inc net income · klrs profit 2025
FY 2025EPS$-2.85▲ +75.70% YoY
202320242025
klrs eps · kalaris therapeutics inc earnings per share 2025
TTM:Revenue: $0.00Net Income: -$44.1MEPS: $-2.15View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy1 analystsis klrs a buy · klrs analyst rating
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$14.00Low
$4.17Current
$18.25Avg Target337.65% upside
$23.00High
klrs price target · klrs 12 month forecast

Total: 1 · Buy rate: 100.0%

The KLRS analyst consensus is Buy, based on ratings from 1 Wall Street analysts over the past 3 months. The average 12-month price target is $18.25, representing +337.65% upside from the current price of $4.17.

Stock Performance

Full History
1D-6.08%
1W-10.52%
1M-17.91%
3M-57.54%
YTD-50.59%
1Y+36.27%
5Y-99.97%

About Kalaris Therapeutics Inc

CEOAndrew Oxtoby
IPO DateJul 30, 2020
Employees14
CountryUS
Websitekalaristx.com

Kalaris Therapeutics Inc operates as a pharmaceutical enterprise. The company's core mission centers on developing innovative cell therapies. These treatments are designed to reactivate the body's in…

BiotechnologyHealthcareNASDAQUS

what is kalaris therapeutics inc · klrs stock overview · kalaris therapeutics inc company profile · who is kalaris therapeutics inc ceo · klrs NASDAQ · kalaris therapeutics inc headquarters · kalaris therapeutics inc business segments

About Stock Overview & Key Data

Kalaris Therapeutics Inc (KLRS) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Jul 30, 2020. As of the latest trading session, KLRS stock price is $4.17, with a market capitalization of $78.0M. The stock has returned +36.27% over the past 12 months and -50.59% year-to-date.

According to 1 Wall Street analysts, the consensus rating for Kalaris Therapeutics Inc stock is Buy, with an average 12-month price target of $18.25. In fiscal year 2025, Kalaris Therapeutics Inc reported revenue of — and net income of -$43.4M. For detailed data — including Kalaris Therapeutics Inc revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, Kalaris Therapeutics Inc (KLRS) stock price is $4.17. The stock is traded on NASDAQ under the ticker symbol KLRS. The 52-week range is $2.14 – $11.88.

KLRS stock priceKLRS quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 9, 2026Not investment advice